CART123 + Ruxolitinib in Relapsed/Refractory AML

NCT06768476 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Relapsed AML
Refractory AML

Interventions

BIOLOGICAL: CART123 Cells
DRUG: Ruxolitinib 10 MG
DRUG: Ruxolitinib 5 MG

Sponsor

University of Pennsylvania

Collaborators

[object Object]